Lisata Therapeutics reported on June 17, 2025, that it now expects its funds will support operations until the fourth quarter of 2026, an extension from earlier guidance of the third quarter. The company stated it has approximately $25.8 million in cash, cash equivalents, and marketable securities as of its last report.